重编程
离体
癌症免疫疗法
免疫疗法
嵌合抗原受体
体内
癌症研究
癌细胞
癌症
免疫系统
T细胞
生物
免疫学
细胞生物学
细胞
生物技术
遗传学
作者
Elana Ben‐Akiva,Johan Karlsson,Stephany Y. Tzeng,Hongzhe Yu,Jordan J. Green
出处
期刊:Elsevier eBooks
[Elsevier BV]
日期:2021-08-27
卷期号:: 31-62
被引量:1
标识
DOI:10.1016/b978-0-323-85781-9.00002-6
摘要
In recent years, the immune system has increasingly been recognized as a critical component to understanding cancer progression and cellular microenvironments. This has led to massive growth in the field of cancer immunotherapy, in which the patient's natural defense mechanisms are harnessed and enhanced to fight cancer. In this field, T-cell engineering has been the most widely studied and developed approach, with checkpoint inhibitors like anti-PD-1 antibody recently showing impressive clinical success for solid tumors and ex vivo engineering of chimeric antigen receptor T-cells making a significant impact on liquid tumors. There has been continued basic and translational research interest in developing engineering technologies for delivery of therapeutic agents to induce T-cell reprogramming both ex vivo and in vivo for cancer immunotherapy. In this chapter, delivery technologies that provide surface stimulation to T-cells (outside-in) as well as technologies that deliver intracellular mediators to T-cells (inside-out) for reprogramming to enhance anti-cancer activity are discussed.
科研通智能强力驱动
Strongly Powered by AbleSci AI